FDA declines to authorize common antidepressant as COVID treatment
By Leroy Leo and Michael Erman (Reuters) – The U.S. Food and Drug Administration has decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying that the data has not shown the drug to be an effective therapeutic for fighting the virus. “Based on the review of available scientific evidence, the FDA has determined …
FDA declines to authorize common antidepressant as COVID treatment Read More »










